Data from a clinical trial led by the University of Michigan Kellogg Eye Center reports patients with Graves' eye disease — also known as thyroid eye disease (TED) — had a significant reduction in symptoms after treatment with study drug teprotumumab.
According to researchers, most TED patients in the trial who received the active drug instead of a placebo experienced reduced eye bulging, eye pain and swelling and improved quality of life. For some patients, the therapeutic benefit reportedly happened quickly — within six weeks of intravenous infusions of the drug.
Researchers reportedly believe their findings suggest teprotumumab may provide substantial benefit to patients and offer a therapy for avoiding complex surgery and preventing vision loss. A follow-up clinical trial is reportedly underway and is expected to be completed in 2018.
The study was recently published in the New England Journal of Medicine.
Click here to read the full press release.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.
Source: University of Michigan